Cooperative Agreement to Support Effective Dissemination of Clinical Practice Guidelines
ID: 356050Type: Forecasted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Award Range

$1M - $1M

Eligible Applicants

Unrestricted

Funding Category

Agriculture

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356050
Timeline
    Description

    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "Cooperative Agreement to Support Effective Dissemination of Clinical Practice Guidelines." This initiative aims to support the dissemination of clinical practice guidelines, particularly those developed with prior FDA cooperative agreements, by requiring applicants to propose a comprehensive plan for developing, evaluating, and distributing materials that facilitate this dissemination, with a strong emphasis on equity. The funding for this opportunity has an award ceiling and floor of $1,000,000, with one award expected to be made in fiscal year 2025. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further information.

    Point(s) of Contact
    Terrin Brown Grantor
    (240) 402-7610
    terrin.brown@fda.hhs.gov
    Files
    No associated files provided.
    Similar Opportunities
    Collaborations to Enhance Drug Development and Regulatory Science
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is inviting applications for a federal grant titled "Collaborations to Enhance Drug Development and Regulatory Science." This opportunity aims to establish cooperative agreements that support Public-Private Partnerships and collaborative activities under the Critical Path Initiative, focusing on innovative projects that enhance drug product development, advanced manufacturing, and the translation of scientific discoveries into therapeutics. The initiative is crucial for fostering innovation in drug safety, efficacy, quality, and performance, with a total funding ceiling of $5 million available for six expected awards in fiscal year 2024. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call (240) 402-7610 for further information.
    Critical Path Public Private Partnerships Clinical Trials Optional
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a grant opportunity titled "Critical Path Public Private Partnerships Clinical Trials Optional," aimed at supporting the continuation of existing consortia groups established by the Critical Path Institute. This initiative seeks applications to manage and maintain these groups, fostering innovative projects in research, education, and outreach to enhance drug product innovation and accelerate the development of therapeutics. The grant, which has an award ceiling and floor of $20 million, is expected to result in one award, with applications being accepted for the fiscal year 2024. Interested applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov or (240) 402-7610 for further information.
    Center for Research on Complex Generics (U18) Clinical Trials Optional
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity for the establishment of a Center for Research on Complex Generics through a cooperative agreement. This initiative aims to enhance collaboration with the generic drug industry, focusing on identifying scientific challenges in generic product development and facilitating research that supports the FDA's mission to improve patient access to high-quality, safe, and effective generic drugs. The Center will serve as a hub for coordination among FDA, academia, and industry stakeholders, conducting research, hosting workshops, and providing public access to research outcomes. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610. The funding amount is set at $1.5 million, with one award anticipated for the fiscal year 2025.
    FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity titled "FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01)," aimed at advancing minority health and health equity objectives. This cooperative agreement seeks innovative research proposals that enhance diversity in clinical trials, improve data availability on diverse populations, and amplify diverse patient perspectives and needs. The initiative is crucial for addressing disparities in health outcomes and ensuring equitable representation in health research. Interested applicants can apply for a funding amount of $1 million, with an expected four awards to be made, and should direct inquiries to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610. The opportunity is set for the fiscal year 2025 and was last updated on August 14, 2024.
    Flexible Funding Model-Infrastructure Development and Maintenance for State Manufactured Food Regulatory Programs (U2F) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity titled "Flexible Funding Model-Infrastructure Development and Maintenance for State Manufactured Food Regulatory Programs (U2F)," aimed at enhancing state manufactured food regulatory programs. This cooperative agreement seeks to support the development and maintenance of Manufactured Food Regulatory Program Standards (MFRPS) to ensure high-quality regulatory frameworks that improve food safety and reduce foodborne illness hazards. Eligible applicants include state, tribal, and territorial food safety programs with existing FDA food safety inspection contracts or those willing to enter into such contracts, with funding amounts ranging from $340,000 to $1,285,000 per year. Interested parties can contact Terrin Brown at terrin.brown@fda.hhs.gov or (240) 402-7610 for further information, with applications expected to align with the fiscal year 2024 timeline.
    Cooperative Agreement to Support Activities Related to Analgesics, Anesthetics, and Addiction (U01) Clinical Trials Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "Cooperative Agreement to Support Activities Related to Analgesics, Anesthetics, and Addiction (U01)," aimed at advancing research in Anesthesia, Addiction Medicine, and Pain Medicine. Applicants are required to propose comprehensive, evidence-based plans that focus on critical areas such as clinical trial endpoints for chronic pain, outcome measures for stimulant use disorders, and assessments of opioid clinical trials, among others. This initiative is vital for enhancing the understanding and management of analgesics and anesthetics, particularly in vulnerable populations. The FDA anticipates awarding five grants, each with a funding ceiling and floor of $2 million, with applications due for the fiscal year 2025. Interested parties can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further information.
    Manufactured Foods Flexible Funding Model (MF-FFM)
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity titled "Manufactured Foods Flexible Funding Model (MF-FFM)" aimed at advancing a nationally integrated food safety system. This cooperative agreement seeks to support initiatives related to Manufactured Food Regulatory Program Standards (MFRPS), dietary supplement safety, and state compliance and enforcement infrastructure, with a focus on enhancing food safety practices across jurisdictions. The program is critical for ensuring that state regulatory programs maintain high-quality standards and best practices in food safety. Interested applicants, which include state, local, territorial, and tribal agencies, as well as non-profit training entities collaborating with higher education institutions, can reach out to Gordana Zuber at gordana.zuber@fda.hhs.gov or by phone at 301-348-1747 for further details. The estimated project start date is July 1, 2023, with approximately 50 awards expected under this discretionary funding opportunity.
    Retail Food Safety Regulatory Association Collaboration CAP
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "Retail Food Safety Regulatory Association Collaboration CAP," aimed at enhancing retail food safety initiatives across the United States. This opportunity is specifically designed for non-profit national organizations affiliated with higher education institutions, whose members include regulatory personnel focused on retail food safety, as permitted by the Food Safety Modernization Act (FSMA). The initiative seeks to reduce foodborne illness by advancing practices in retail food protection, conducting relevant research, and fostering collaboration among stakeholders. The total funding available for this opportunity is $4 million, with an expected five awards to be made, and interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610 for further details.
    FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering the Health Equity Innovation Award (U01) to fund innovative research aimed at enhancing minority health and advancing health equity objectives. This funding opportunity focuses on proposals that promote diversity in clinical trials, improve data availability on diverse populations, and amplify the voices of underrepresented patient groups. With an award ceiling of $1 million and a floor of $250,000, the FDA anticipates making four awards in fiscal year 2024. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further information.
    Animal Food Regulatory Program Alliance
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "Animal Food Regulatory Program Alliance," aimed at enhancing the national food safety system through improved collaboration among federal and state agencies. The primary objective of this program is to support the development of a national integrated animal food safety system, which includes sharing best practices, conducting training programs, and advancing the Animal Food Regulatory Program Standards (AFRPS). This initiative is crucial for ensuring public health and consumer protection in the regulation of manufactured foods. Interested national associations or organizations that represent state animal food regulatory programs can apply for funding, with a total award amount of $600,000. For further inquiries, applicants may contact Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610. The fiscal year for this opportunity is 2025.